Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). Gynecol Oncol. 2017;144(2):396-404. [Šekerija M]
Autori: Matz M,
Coleman MP,
Carreira H,
Salmeron D,
Chirlaque MD,
Allemani C,
CONCORD Working GroupGodina: 2017
Erratum to “Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)” [Gynecol. Oncol. 144 (2017) 396-404]. Gynecol Oncol. 2017;147(3):725. [Šekerija M]
Autori: Matz M,
Coleman MP,
Carreira H,
Salmeron D,
Chirlaque MD,
Allemani C,
CONCORD Working GroupGodina: 2017
(Šekerija M) Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977-1010.
Autori: Allemani C,
Weir HK,
Carreira H,
Harewood R,
Spika D,
Wang XSGodina: 2015
